Lyon, France and Cambridge, MA (PRWEB UK) 15 March 2013
Mérieux Développement, the private equity arm of the Institut Mérieux group, announced today that Jean-Marie Vogel has joined the firm as Senior Partner based in Cambridge, MA, to foster the firm’s US investments and support small and mid-cap healthcare companies through minority investment and active board membership. This new addition further complements the capabilities of Merieux Développement in the US, where the firm has been active through direct investments since 2010. Mr. Vogel’s addition expands Mérieux Développement’s presence in the US, and follows the appointment of Isaac Bright, M.D., who recently joined the team out of San Francisco, CA.
Jean-Marie Vogel brings to Mérieux Developpement a solid track-record establishing, leading, and financing innovative healthcare companies. In 2003, he co-founded Pluromed, Inc., a breakthrough vascular and cardiovascular medical device company, and served as its CEO until its acquisition by Sanofi in 2012. From 2002 to 2005, he served as CEO of Cryoma Laboratories, an autologous tumor cell bank to help cancer patients, which was sold to Cancer Therapeutics in 2005. In 1999, Jean-Marie founded BioSphere Medical, a leading interventional oncology company and the world leader in embolotherapy, where he served as its Chairman until 2002. The company was later acquired by Merit Medical. From 1994 to 1999, he served as CEO of BioSepra, Inc., a leader in process chromatography for monoclonal antibodies and gene therapy, after having co-managed its public spin-off from Sepracor, Inc. BioSepra was sold to Life Technologies in 1999. Prior assignments included President of Cuno Europe, based in Paris, France and various commercial leadership positions for Millipore Corporation in Europe, Africa, Asia and the United States. Jean-Marie Vogel graduated in Applied Mathematics from Ecole Centrale de Paris, one of the leading engineering schools in France.
About Mérieux Développement
Mérieux Développement is the private equity arm of the French group, Institut Mérieux, which has 12,000 employees worldwide and generated revenues of EUR 1.7B in 2011. Other companies in the group include bioMérieux (in vitro diagnostics), Mérieux NutriSciences (food safety, nutrition-related CRO services), Transgene (immunotherapy, biotechnology) and Advanced BioScience Laboratories, Inc (CRO specialized in vaccine development). Mérieux Développement invests in the healthcare sector on a global basis, working alongside entrepreneurs whose products and services can bring genuine advances to the health of patients and consumers worldwide, offering them access to its industry expertise and global network.
More information is available at: http://www.merieux-developpement.com